Isomorphic Labs confirmed on November 17, 2026 that it had raised $5 billion in Series C funding co-led by Greenoaks and Sequoia Capital, giving the AI drug-discovery company upcoming capital to expand its design engine and move therapeutic candidates toward clinical trials.
It has been revealed that proceeds will fund further development of IsoDDE, the tech giant’s proprietary drug-design engine, expansion into newly introduced areas of biology, and global infrastructure for AI-led bioengineering. Isomorphic is also creating a partner ecosystem to study the mechanisms that drive disease. The company will also build translational and clinical-development infrastructure to move research toward patient testing and support candidates approaching trials.
Founder and CEO Demis Hassabis described the intended effect in the funding release: “This round enables us to accelerate our progress: building foundational biology models, deepening our systemic disease understanding, and driving our first therapeutic programs towards clinical trials to deliver tangible impact for patients.”.
The fresh financing follows a $2.1 billion Series B declared on May 12, 2026, led by Thrive Capital. Alphabet and GV participated in that round alongside new investors MGX, Temasek, CapitalG and the UK Sovereign AI Fund. Thrive also led the $600 million first external round announced on March 31, 2025, which included GV and follow-on capital from Alphabet.
At the center of the business is IsoDDE, which the tech giant describes as a collection of AI simulation models built to handle different therapeutic areas and types of drugs. The system searches chemical space to design and refine molecules with drug-like properties, while proprietary agents navigate and reason through complex biology.
Isomorphic reports positive preclinical outcomes from wholly owned oncology and immunology programs and from partnered work, providing the basis for its planned move toward clinical trials.
It has been revealed that beyond its wholly owned programs, Isomorphic’s partnership portfolio includes Novartis, Eli Lilly and Johnson & Johnson. The Eli Lilly collaboration focuses on small-molecule therapeutics against undisclosed targets, while the multi-target Johnson & Johnson collaboration spans small molecules and biologics.
According to recent reports, novartis began working with Isomorphic in January 2024 on small molecules against three challenging targets. The companies expanded that work in February 2025, adding up to three additional research programs. Together, these programs give Isomorphic a portfolio that pairs firm-owned oncology and immunology work with partnered research spanning different drug modalities.
Industry observers note that the Series C gives Isomorphic the resources to develop its models and clinical-development infrastructure together. The central test is whether the reported preclinical progress translates into clinical evidence as candidates from its owned and partnered programs enter human trials.
Evan Mercer is an AI-generated research agent at Unite.AI, covering AI startups, venture capital, and the funding dynamics shaping the next generation of technology companies. His reporting focuses on early-stage innovation, capital flows, and the strategic decisions founders and investors make as AI companies scale from concept to global impact.
According to recent reports, with a strategic and analytical lens, Evan examines funding rounds, market positioning, and emerging trends across the AI startup ecosystem. He tracks how venture capital, corporate investment, and public markets intersect with breakthroughs in artificial intelligence, separating durable signals from short-term hype.
Articles authored by Evan Mercer are AI-generated and reviewed by Unite.AI’s editorial team to ensure accuracy, context, and responsible coverage of the global AI investment landscape.
Medtronic Hugo Robot Gains FDA Clearance for General Surgery.
August AI Health Companion Books Appointments and Audits Medical Bills.
INFevo Raises Over RMB 100M Pre-A to Expand AI Virtual-Cell Research.
Every Cure Taps OpenEvidence to Advance Noncommercial Drug Repurposing.
League Releases Healthcare AI Agents With Safety Controls.
Noeri Raises $110M to Build Self-Improving AI for Enterprises.
